|
|
|
| The Effect of Irbesartan and Benazepril on Coronary Artery Disease and Hypertension in Patients With Vascular Endothelial Function |
| Dong Chunfang, Zheng Shuaijun, Xu Haojie |
| Traditional Chinese Medicine Hospital of Sui County,Internal Medicine Ward Six,Sui County 476900,China |
|
|
|
|
Abstract Objective To compare the effects of irbesartan and benazepril on coronary artery disease（CHD） with hypertension（EH） on vascular endothelial function parameters.Methods A total of 120 patients with CHD and EH were selected as test subjects and randomly divided into a study group and a control group of 60 cases each.The control group was treated with benazepril and the study group was treated with irbesartan.The changes of vascular endothelial function indexes（NO,ET-1） and morning blood pressure（DBP,SBP） of the two groups of patients were compared before and after 1 month of treatment,and the differences in adverse drug reactions within 1 month of treatment were analyzed.Results After 1 month of treatment,the levels of NO in the two groups were significantly higher than before treatment,and the study group was significantly higher than the control group in the same period（P<0.05）.The levels of ET-1 in the two groups were significantly lower than before treatment,and the study group was significantly lower than the control group at the same time（P<0.05）.In the morning,the levels of DBP and SBP in the two groups were significantly lower than before treatment（P<0.05）,and the levels of DBP and SBP between the two groups were not statistically significant（P>0.05）.Within 1 month of treatment,the incidence of dry cough in the study group was significantly lower than that in the control group（P<0.05）.There were no significant differences in other adverse drug reactions（P>0.05）.Conclusion Irbesartan is effective in treating CHD with EH,which is equivalent to benazepril,but irbesartan can significantly improve the level of vascular endothelial function in patients with CHD and EH,and the safety is better than benazepril,which is beneficial to the recovery of patients' prognosis.
|
|
Received: 15 December 2019
|
|
|
|
|
|
[1] 郑刚. 2015年最新发表的高血压相关指南及研究进展解读[J].世界临床药物,2016,37(11):721-724.
[2] 沈迎,张奇,沈卫峰.美国和欧洲稳定性冠心病诊治指南解读[J].中华心血管病杂志,2014,42(1):70-72.
[3] 张菀桐,胡元会,朱宝琛,等.冠心病合并高血压患者血压水平与血栓形成动力学相关性研究[J].现代中西医结合杂志,2016,25(2):129-131.
[4] 陈橙,孙长贵.贝那普利与缬沙坦联合治疗肾性高血压的临床疗效及对肾功能的影响[J].心血管康复医学杂志,2016,25(5):504-507.
[5] 龚芸. 厄贝沙坦联合小剂量利尿剂对老年单纯收缩期高血压患者血清炎症因子及血管内皮功能的影响[J].实用临床医药杂志,2019,23(4):54-56. |
| [1] |
Li Guangyun. Retrospective Study of Simvastatin Tablets Combined With Enalapril Folic Acid Tablets in the Treatment of Patients With Hypertension and Hyperhomocysteinemia[J]. journal1, 2021, 41(5): 3-4. |
| [2] |
. [J]. journal1, 2021, 41(5): 98-98. |
| [3] |
. [J]. journal1, 2021, 41(5): 131-132. |
| [4] |
. [J]. journal1, 2021, 41(2): 45-46. |
| [5] |
. [J]. journal1, 2021, 41(2): 53-53. |
| [6] |
. [J]. journal1, 2021, 41(2): 118-119. |
|
|
|
|
2021, Vol. 41 
